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Introduction
Breast cancer is the most common cancer 
in women worldwide (1,2). Locally in 
Kenya, breast cancer accounts for 23.3% 
of cancer mortality amongst women (3,4). 
It affects young to middle-aged women 
in the 35- to 55-year age group and has a 
prevalence of 34/100,000 (3,5). In the 2014 
World Health Organization (WHO) report 
Abstract
Purpose: To establish the prevalence of cancer in patients referred for breast ultrasound-
guided biopsy at Kenyatta National Hospital, Nairobi, Kenya.
Methods and Materials: A total number of 115 patients were included after approval from 
the local ethical review committee. The patients were referred by clinicians for ultrasound-
guided biopsy for palpable breast lesions confirmed by imaging as solid masses. Detailed 
ultrasound examination per American College of Radiology (ACR) guidelines was performed 
before core biopsy or fine needle aspiration (FNA). Histological diagnosis was made and 
prevalence of cancer analyzed.
Results: Of the 115 patients, final histology was available for 112 lesions; two cases could not be 
traced and one was inconclusive. Females accounted for 96.5% of cases; median age 28 years 
(range of 15-79 years). Median age of patients with cancer was 48 years (range 28-79 years). 
Cancer was diagnosed in 28 (25%) specimens, the remaining 84 revealing benign histology, 
with 74/84 (88%) fibroadenomas. There were 32/112 patients aged > 40 years (28.6%), of which 
22 (78.6%) had cancer (p < 0.0001). BIRADS final assessment categories were assigned prior 
to biopsy; all solid masses in BI-RADS 2 and BIRADS 3 were histologically benign.   One  of 11 
lesions in BIRADS 4 category, and 2 of 20 in BIRADS 5 were histologically benign. Elastography 
assisted in identifying all cancers in these groups as suspicious, based on strain ratio. 
Conclusion: Most breast masses in our cohort (75%) were benign. Patients with a breast 
lump, especially young ones, need not assume it is cancer until thorough clinical and imaging 
evaluation has been done to characterize lesions and biopsy performed when indicated. Of 
the 25% of patients with cancers in this study, almost 79% were > 40 years of age; younger 
women had benign lesions, mostly fibroadenomas. 
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on causes of death and population dynamics, breast cancer 
in Kenya accounted for 0.56% of all deaths. The Kenyan age 
standardized rate (ASR) incidence of breast cancer between 
2004 and 2008 was 51.7 per 100,000 (6). Kenya does not 
have a national breast cancer screening program, but cancer 
awareness is created through media and medical forums that 
encourage self-breast examination and advise women to seek 
medical attention if a mass is found or suspected. Voluntary 
annual mammographic screening from 40 years of age is also 
advocated in many of these forums. The risk of breast cancer is 
higher in developed countries than in low-income countries, 
with the highest number of cases being found in Western 
Europe and North America (8,9). Studies estimate that 1 in 8 
American women (about 12%) will develop invasive breast 
cancer over the course of their lifetime (10). The etiological 
factors leading to high risk of breast cancer in the developed 
world compared to poorly resourced countries (PRCs) is 
not known; however, lifestyle and reproductive factors are 
thought to play a role (9). In Kenya, there has been an increase 
in breast cancer which may in part be attributed to changes in 
lifestyle habits, including adoption of known cancer-causing 
behaviors such as smoking and diets that may lead to obesity 
(7). 
There is also the issue of low utilization of screening, and 
inadequate documentation of breast cancer cases in PRCs 
which may be a contributing factor to the assumed and 
possibly false “lower” incidence and risk in these regions 
(11,12). Other known risk factors for development of breast 
cancer include female gender, older age, family history, BRCA 
and other gene mutations, as well as obesity (9). However, 
documentation of some of these factors is not available in 
PRCs; specifically, BRCA testing is not established in most 
countries within Africa (13,14). 
Since there is no national screening program in Kenya, breast 
cancer usually presents as a palpable lump, raising great 
concern and sometimes leading to extensive investigations, 
including invasive procedures such as biopsies. Kenya 
Ministry of Health guidelines published in 2012 advocate 
for triple assessment of palpable and mammographically 
detected breast masses (11). The triple assessment combines 
clinical breast examination, mammography or other imaging 
such as US, and tissue sampling using fine needle aspiration 
(FNA) cytology or biopsy (15). While diagnostic ultrasound 
(US) evaluation may help characterize masses as possibly 
benign and not requiring biopsy, most cases undergo 
image-guided core needle biopsy (US-CNB), FNA, or surgical 
excision, limiting the potential benefit of diagnostic US. We 
have encountered in our practice and experience such cases 
where some clinicians and patients want all masses to be 
subjected to FNA or core biopsy to allay patient anxiety. Such 
experiences motivated us to carry out this study and assess 
the prevalence of breast cancer among patients presenting 
with breast masses and referred for US-guided biopsies or 
FNA. 
The purpose of this study was to determine the prevalence 
of histologically diagnosed cancers in patients with palpable 
solid breast masses referred for US-guided biopsies at 
Kenyatta National Hospital (KNH), Nairobi, Kenya. 
Methods and materials
This was a prospective study carried out from May to December 
2014. Subjects were all patients with known or suspected 
breast masses, referred to the Radiology Department for 
US-CNB. Most patients came from clinics within Nairobi and 
neighboring counties. Approval was sought from the KNH/
University of Nairobi (UON) ethical committee and granted 
before the study commenced. Patients who had known 
histology and/or declined consent to participate in the study 
were excluded. A total number of 118 patients were recruited. 
After adequate explanation of the study and procedure, 115 
consented. Prior to tissue sampling, detailed US evaluation 
of both breasts was performed to scout for any additional 
masses, all masses were characterized as likely benign or 
malignant, and final assessment categories were assigned 
using the ACR BI–RADS lexicon. Correlation was made with 
final histology.
Breast US was performed per American College of Radiology 
(ACR) guidelines (16) to confirm masses, find any additional 
masses and characterize the masses based on US features. 
All exams were performed and interpreted by one of three 
radiologists, one of whom had 10 years’ experience and the 
other two 5 years each. Two of 115 patients had no mass, while 
one patient had an additional mass in the same breast, and 
two had an additional mass in the contralateral breast. All US 
exams were performed using a GE (General Electric, Boston, 
MA, USA) Logiq S7 machine with B mode, color Doppler and 
elastography, utilizing a high frequency 8-13 MHz transducer. 
All scans were performed by qualified sonologists experienced 
in breast ultrasound, and included bilateral whole breast and 
axillary examination. The lead researcher (AAA) in this study 
had completed her ultrasound fellowship training at Thomas 
Jefferson University (Philadelphia, PA, USA). Although all 
solid masses had been referred for tissue sampling, we 
classified the lesions using the ACR BI-RADS final assessment 
categories. Evaluation included sono-elastography recording 
the elastography strain scores for each mass with the ratio 
cut-offs of 3 and 4.2, respectively.
All tissue sampling procedures were performed using 
standard aseptic technique and real-time US guidance, under 
local anesthesia. 
BIOPSY PROCEDURE:
Informed free consent was obtained from each patient, after 
the need for the study and technique of the procedure was 
clearly explained to each patient.
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Core biopsy of breast masses has low incidence of 
complications and generally requires no pre-biopsy laboratory 
tests, except in patients with known coagulopathy or those 
on anticoagulant medications. None of the study patients 
had such history, obviating the need for laboratory work or 
withdrawal of medications. All procedures were performed 
under strict asepsis. No antibiotics were administered after 
biopsy. 
A free-hand biopsy technique was used where the ultrasound 
transducer was held with one hand, while the biopsy device 
attached to a 16-18 gauge needle, in the other. Core biopsies 
were performed after a tiny nick in the skin, and using a spring-
loaded 16-gauge Bard biopsy system. FNA were performed 
using a 23-gauge needle. 
In most cases, four samples were obtained from different 
areas of the lesion: center, 12, 6, 3, and 9 o’clock positions. 
After biopsy the area was checked sonographically to check 
for any complication, hemorrhage or injury to the chest wall. 
We encountered no complications. 
When we were satisfied that appropriate samples had been 
taken, the incision area was compressed for five minutes and 
a sterile compressive dressing applied to be in place for 24 
hours. The patient was advised to avoid excessive physical 
exercise and take non-steroidal anti-inflammatory pain tablets 
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Figure 1. Distribution of the patients according to different 
age groups. Figure 2. Proportion of malignant and benign lesions.
Figure 3: Frequency of benign and malignant lesions among different age groups.
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as necessary. The specimens were sent to the appropriate 
high-end laboratories in University of Nairobi histology and 
cytology labs for histology or cytology.
FNA was performed in 23 cases using the appropriate FNA 
procedure. Gauge 23 needles were used and three samples 
per lesion were taken and the slides placed in 95% alcohol. 
Histopathologic and cytology examinations were conducted 
by pathologists with over 15 years’ experience in breast and 
general pathology. 
Descriptive statistics, including frequencies, measures of 
central tendency and spread, were analyzed using MS Excel® 
and SPSS® software. Significance of difference among different 
age groups was also calculated using Fisher’s exact test. 
Results
Out of 115 patients who consented for the study, two patients 
had no mass lesion and were therefore excluded from biopsy, 
leaving 113 patients, median age 28 years (range: 15-79 years) 
(Figure 1). An extra mass was seen in three patients, leading 
to identification of 116 masses for biopsy/cytology. Biopsy 
results were lost in two cases, and two biopsy results were 
inconclusive, leaving a final study population of 112; 108 
(96.5%) females and 4 (3.5 %) males. Of the 112 cases that 
were fully evaluated, 89/112 (79.5 %) underwent CNB, and 
23/112 (20.5 %) underwent FNA. All four male patients had 
benign lesions: two were lipomas, and the other two, who 
had family history of breast cancer, were found to have 
glandular hypertrophy in the affected breast. Cancer was 
diagnosed histologically in 28/112 (25%) biopsy specimens, 
with the remaining 84/112 (75%) revealing benign histology. 
All the cancers in our study were invasive ductal carcinomas, 
which are the most common breast cancers worldwide. Of the 
benign lesions, there were 74/84 (88%) fibroadenomas (Figure 
2). No cancers were found in the <25 years age group (Figure 
3); the youngest cancer patient was 28 years old. Of the total 
study population, there were only 32 (28.6%) patients >40 
years of age, but they accounted for 22/28 (78.6%) cancers 
(Table 1) (p <0.0001). 
Our study found that BIRADS 5 had the largest number of 
Table 1. Demonstrating lesion distribution with a cutoff at 40 years of age.
Benign Malignant Total 
Less than 40 years 74 6 80
40 years and above 10 22 32
Total 84 28 112
BIRADS
Histology Classification 
Total % Malignant 
Malignant Benign
2 0 73 73    0
3 0 8        8    0
4 10 1 11    90.9
5 18 2 20    90
Total 28 84 112   25
Table 2. Proportion of malignant lesions per BI RADS category. 
All BIRADS 2 and 3 were confirmed benign histologically.
 
 Strain ratio
 
Histology Classification 
 Total 
Malignant Benign 
Malignant 28 3 31 
Benign 0 81 81 
 Total 28 84 112 
Table 3. Comparison of ultrasound and histology. 
All sonograghically benign masses were proven histologically benign.
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cancers, while no cancer was seen in the BIRADS 2 and BIRADS 
3 categories. Of the 20 BIRADS 5 masses, 18 (90%) were proven 
malignant. Of the 11 BIRADS 4, one was found benign and 
10/11(90.9%) were proven malignant (Table 2), giving a total 
of 28 cancers of the 112 total cases (25%) in the study. 
Regarding elastography criteria, as stated above, strain 
score and strain ratio cut-offs of 3 and 4.2, respectively, 
were used. These cut-offs were generated by receiver 
operating characteristics (ROC) curves in retrospect after 
histopathology. All 81 cases categorized as benign by BIRADS 
were also confirmed benign on histology (Table 3). Three 
lesions classified as probably malignant by elastography 
were found benign on histology (all had fibrotic changes 
due to previous infection). Ultrasound distinction between 
malignant and benign lesions using the BI-RADS lexicon and 
elastography is summarized in Figures 4a and 4b. 
Discussion
Findings from this study have led to strict adherence to 
sonographic BIRADS standards for evaluation of all breast 
masses referred for ultrasound guided biopsy in our hospital.
Lesions that are benign after thorough sonographic 
evaluation and categorized as BIRADS 2 on imaging are not 
biopsied while those assessed as BIRADS 3 are recommended 
for follow-up in 6 months. All BIRADS 4 and 5 undergo biopsy. 
Lesions in BIRADS 4 and 5 that turned out histologically 
benign included cases with previous scar and infections that 
had healed and showed fibrotic changes on histopathology.
Our 25% rate of cancer amongst breast masses undergoing 
biopsy is in keeping with several other studies reported from 
other African countries in which benign masses accounted for 
68-70% of the cases (16-20). One local study evaluating pattern 
of breast diseases in 1172 cases at the Kenyatta national 
hospital breast clinic found distribution of pathology at 22% 
malignant and 78% benign, which is close to our findings (26). 
Our results differ from one study from Rwanda in which the 
malignancy rate was 55% of all breast masses undergoing 
biopsy (21). Such a high prevalent rate of malignancy was 
attributed to previous absence of diagnostic access in the 
area. In terms of frequency, most cancers in our study were 
seen in the 40-54-year age group, with the youngest patient 
being 28 and the oldest 79 years old. This finding differs 
from studies in developed countries where breast cancer 
affects older populations, probably due to differences in 
demographic age patterns. As a developing country, Kenya 
has a life expectancy lower than that in the developed world. 
According to the Kenya demographic profile, the 2017 female 
life expectancy is 65.5 years. It should be noted that there 
were only 8 patients above 55 years old in our study, and 6 
of them were diagnosed with cancer. Our study findings also 
correlated favorably with those in China with regards to age 
distribution (22).
From observations derived from our study, overenthusiastic 
utilization of triple test assessment protocol will lead to every 
palpable breast mass undergoing invasive cytology or core 
biopsy procedure. We believe some of these procedures can 
be avoided through imaging undertaken by qualified and 
competent radiologists. BI-RADS lexicon-based assessment 
has been shown to be highly predictive of the likelihood of 
malignant or benign results of breast masses (27-29). 
Strict application of BI-RADS criteria would have avoided 
invasive procedures in 81 (72.3%) patients in our cohort, 
saving the patients from the pain, discomfort, anxiety and 
cost of invasive diagnostic tests. 
The Kenyan breast mass work-up guidelines require highly 
trained and experienced radiologists and technologists, but 
such resources may not be widely available. In reality, in the 
settings of PRCs, local factors such as available equipment, 
personnel expertise and laboratory facilities generally 
determine how diagnoses in breast masses are managed. 
For this reason, we believe, our report does not replicate the 
experience of other imaging centers within the country, the 
region or in many PRCs. However, this issue is beyond the 
scope of this paper. 
Figure 4a. Typical examples of malignant lesions (BI 
RADS 4). These lesions were found to be positive on 
histopathology. 
Figure 4b. Typical example of benign (BI-RADS 2) mass. 
All such category masses were found to be benign on 
histology.
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Various studies have demonstrated that teaching hospitals 
generally offer a higher quality care (23,24). One example is 
a study published by Shahian et al., conducted in the United 
States (23). In this study, teaching hospitals were associated 
with advanced technologies and superior clinical capabilities. 
The setting of our study was a teaching and referral center, 
where we are actively involved in training imagers in a bid 
to build capacity in breast imaging. A similar study in Nigeria 
within a similar setting also gave high diagnostic accuracy of 
ultrasound in women with symptomatic breast pathology (24). 
From Uganda, a 2010 study conducted in the largest teaching 
and referral hospital showed lower sensitivity and specificity 
than ours (25). We attribute this to the fact that the machine 
we used for our study was a higher-end model integrating 
higher frequency and elastography. We note that there are 
scant studies from non-teaching hospitals within our region 
on diagnostic accuracy of breast ultrasound. A larger study 
within our country and region needs to be conducted to 
validate our findings, since ours was only a small, prospective 
one. 
Our study has some limitations: the total study population 
is small; and FNA or biopsies were carried out for all lesions, 
regardless of BIRADS-based US assessment, as per the local 
guidelines which informed the surgeons’ management 
practice of referring all breast masses for biopsy, instead of 
for diagnostic evaluation only. Due to this practice, diagnostic 
imaging is not utilized as much as it potentially could be. 
Conclusion
Most breast masses in our study cohort were benign, with 
only 25% histologically proven malignant. Specifically, most 
masses in the younger, <40 age group in this study were 
benign fibroadenomas. Given these results, we believe 
that properly used US evaluation can reduce unnecessary 
biopsies, especially in patients under 40 years of age. We 
encourage a complete diagnostic US examination for all 
patients referred for tissue sampling of breast masses. 
However, patients with high risk for breast cancer, especially 
strong first-degree family history, can be handled on a case-
by-case basis.
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